Korean Lipolytic Products: A Practitioner's Guide to Selection and Use
Korean manufacturers have been producing pharmaceutical-grade lipolytic injectables for over two decades — longer than any other national market. The Korean aesthetic market's high volume, regulatory rigour, and clinical experimentation across multiple applications have produced a depth of lipolytic product knowledge embedded in Korean formulations that European manufacturers have not yet matched. For UK and EU practitioners, this translates to a choice of CE-marked, MFDS-approved DCA and PC/DCA products that offer pharmaceutical-grade quality at 30–50% lower wholesale cost than European alternatives.
DCA vs PC/DCA: Choosing the Right Lipolytic Agent for Your Patient
Two agents dominate injectable lipolytic practice: deoxycholic acid (DCA) as a single agent, and phosphatidylcholine combined with deoxycholic acid (PC/DCA) as a combination formulation. Both destroy subcutaneous fat cells, both produce the inflammatory clearance response that delivers the result, and both are available as CE-marked Korean formulations at Celmade. But they are not identical — and practitioners who understand the specific differences between them are better positioned to choose the right product for each clinical situation.
Submental Fat Reduction with Injectables: Patient Selection and Injection Protocol
Submental fat reduction — the non-surgical treatment of the area beneath the chin that patients refer to as a 'double chin' — is the most evidence-supported, most precisely understood, and most widely practised injectable lipolytic application in aesthetic medicine. The zone has a defined fat compartment with reasonably predictable anatomy, a pharmaceutical-grade active agent with multiple Phase 3 RCTs behind it (deoxycholic acid, branded as Kybella/Belkyra), and a well-characterised safety profile built from extensive clinical experience.
